Addendum
Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Addendum to Commission A23-66
Report documents
-
Addendum
Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Addendum to Commission A23-66
Dossier assessment
Indication:
Adults with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy
Result of dossier assessment:
- If high-dose therapy is an option: Unchanged after addendum: added benefit not proven
- If high-dose therapy is not an option: Unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-12-21 A G-BA decision was published.
Project details
- Project no.
- A23-106
- Commission
- Commission awarded on 08.11.2023 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://dx.doi.org/10.60584/A23-106
Connected Projects
-
Dossier assessment
Axicabtagene ciloleucel (diffuse large B-cell lymphoma, second line) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed